bevantolol has been researched along with Kidney Diseases in 1 studies
bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The kinetics of the drug (including plasma drug levels, plasma half-life and plasma clearance) and its effects on renal function were observed for 24 hours." | 1.27 | Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function. ( Campese, VM; Massry, SG; Solimon, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solimon, M | 1 |
| Massry, SG | 1 |
| Campese, VM | 1 |
1 other study available for bevantolol and Kidney Diseases
| Article | Year |
|---|---|
Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Creatinine; Glomerular Filtration Rate; Humans; Inulin; Ki | 1986 |